BioSig (BSGM) 10-Q2021 Q1 Quarterly report

Filed: 17 May 21, 5:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AI, aim, Alexander, analyze, artificial, Asirvatham, back, Beacon, Bend, bill, Blvd, body, canceled, Carriage, Church, complaint, Court, customer, dataset, default, delivered, depict, District, Draper, environmental, equivalent, essential, Expansion, found, Fourth, free, guidance, hardware, House, inaccurate, Innovation, invoiced, Keeler, lawsuit, machine, maintenance, mapping, Memorial, Methodist, negotiated, nil, Overland, package, principle, promised, proper, ratably, realigned, reassessed, recovery, Regional, Reified, relief, remeasured, Samuel, saturation, sector, statistically, Suite, unbilled, unconditional, vigorously, visible, warehousing, Warranty, Wilshire

Removed: accepting, accredited, adjustment, amplifying, anticipated, antiviral, approve, assist, attention, banking, biomedical, Branch, broad, building, candidate, cell, charge, China, closing, collection, combination, community, computerized, controlled, coping, corporate, corrective, created, CT, debarment, decreased, deducting, delayed, demonstrate, description, design, digitizing, directly, discontinue, disease, displaying, distribution, divert, downturn, eliminated, enabled, endpoint, enroll, entering, establishment, expensive, filtering, fully, gain, Galveston, globally, government, governmental, halted, higher, hold, hospitalized, impacted, IMPDH, implement, inadequate, inclusive, inconclusive, Incorporation, indirectly, inhibitor, intended, interpreting, investigational, investment, Laidlaw, licensure, listed, local, maintain, manuscript, marketplace, meeting, member, MN, national, nature, Norwalk, obtained, order, paying, PBC, phase, preclinical, production, prolongment, protocol, published, range, raw, receive, remdesivir, replication, responsible, RNA, safety, sanction, schedule, scheduled, SEC, secure, shift, spectrum, spread, storage, storing, strain, sublease, submitted, subsequent, sum, supervise, supervision, supply, surfaced, target, testing, title, trademark, trial, UK, undergoing, understanding, underwriter, underwriting, underwritten, unknown, utility, vary, Vertex, vitro, Weild, Westport, widespread, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BSGM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.01

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Kenneth L. Londoner, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioSig Technologies, Inc.


	By:	/s/ Kenneth L. Londoner
Date: May 17, 2021	Name:	Kenneth L. Londoner
	Title:	Chairman & Chief Executive Officer (Principal Executive Officer)

I, Steven Chaussy, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioSig Technologies, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioSig Technologies, Inc.


	By:	/s/ Steven Chaussy
Date: May 17, 2021	Name:	Steven Chaussy
	Title:	Chief Financial Officer (Principal Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.